Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a Healthcare company (Biotechnology) with a market capitalization of $4.6B. The Maz Rating grades it against the other companies in its sector.
Adaptive Biotechnologies Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $28.49, Adaptive Biotechnologies Corporation trades at 15.5x sales and 25.9x book value. Over the last twelve months it generated about $298M of revenue and a net loss of $73M. It runs a gross margin of 74.0%, an operating margin of -16.2% and a net margin of -23.7%. It shows return on equity of -37.4%, return on invested capital of -8.1% and a free cash flow yield of -0.2%. On the balance sheet: a debt-to-equity ratio of 2.32 and a current ratio of 3.97. Over the past 52 weeks the share price ranged from $12.00 to $32.21, with a beta of 2.15.
Adaptive Biotechnologies Corporation does not currently pay a dividend.
17 Wall Street analyst ratings cover the stock: 11 Buy, 4 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.